Jabado, Omar
Maldonado, Michael A.
Schiff, Michael
Weinblatt, Michael E.
Fleischmann, Roy
Robinson, William H.
He, Aiqing
Patel, Vishal
Greenfield, Alex
Saini, Jasmine
Galbraith, David
Connolly, Sean E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
SAT0041 Efficacy of abatacept versus adalimumab in patients with seropositive, erosive early ra: analysis of a randomized controlled clinical trial (AMPLE)
https://doi.org/10.1136/annrheumdis-2017-eular.3521
THU0089 M-DAS28, DAS28 (CRP) and RAPID3 scores at baseline are good predictors of radiographic disease progression at 1 and 2 years: data from the ample trial
https://doi.org/10.1136/annrheumdis-2017-eular.1930
POS0474 SUBSTANTIAL IMPACT OF AUTOANTIBODY ENRICHMENT ON OUTCOMES IN EARLY RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: DATA FROM A LARGE POOLED ANALYSIS OF 4 RCTS
https://doi.org/10.1136/annrheumdis-2021-eular.2513
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
https://doi.org/10.1136/annrheumdis-2015-207942
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
https://doi.org/10.1136/rmdopen-2015-000210
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
https://doi.org/10.1007/s40744-021-00404-x
SAT0108 Efficacy of abatacept versus adalimumab on the proportion of patients with seropositive, erosive early ra achieving das28 (CRP) <2.6 or validated measures of remission: a post hoc analysis of the 2-year ample trial
https://doi.org/10.1136/annrheumdis-2018-eular.2333
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Received: 13 August 2021
Accepted: 17 November 2021
First Online: 8 December 2021